Erythrocyte aldose reductase and diabetic neuropathy. Implication in the efficacy of aldose reductase inhibitor
نویسندگان
چکیده
منابع مشابه
Topical aldose reductase inhibitor.
amblyopia: a comprehensive survey of outcome. Eye 1992; 6: 300-4. 7 Lithander J, Sjorstrand J. Anisometropic and strabismic amblyopia in the age group 2 years and above: a prospective study of the results of treatment. retinoscopy by used to screen infants for amblyopia? A longitudinal study of refraction in the first year of life. Polymegathism is a term used to describe increased variability ...
متن کاملErythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy
PURPOSE Activation of polyol pathway due to increased aldose reductase (ALR2) activity has been implicated in the development of diabetic complications including diabetic retinopathy (DR), a leading cause of blindness. However, the relationship between hyperglycemia-induced activation of polyol pathway in retina and DR is still uncertain. We investigated the relationship between ALR2 levels and...
متن کاملCorrelation between erythrocyte aldose reductase level and human diabetic retinopathy.
AIM To examine the relation between aldose reductase (AR) and the development and progression of diabetic retinopathy by comparing the erythrocyte AR levels with the prevalence of diabetic retinopathy in NIDDM patients. METHODS A clinic based cross sectional study was used. 611 NIDDM patients and 73 controls were enrolled. Erythrocyte AR levels were determined by ELISA. These AR levels were t...
متن کاملEnzyme immunoassay for erythrocyte aldose reductase.
This two-site immunoassay measures erythrocyte aldose reductase by using monoclonal and polyclonal antibodies to recombinant human enzyme. Total incubation time is 2.5 h, and the limit of detection is < 0.05 microgram/L. Analytical recovery tested with blood samples from healthy and diabetic individuals was 101-106%. Average CVs within and between assays were 3.7% and 4.8%, respectively. The en...
متن کاملLong-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
OBJECTIVE We sought to evaluate the long-term efficacy and safety of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. RESEARCH DESIGN AND METHODS Subjects with diabetic neuropathy, median motor nerve conduction velocity (MNCV) >or=40 m/s, and HbA(1c) <or=9% were enrolled in this open-label, multicenter study and randomized to 150 mg/day epalrestat or a control gro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacology
سال: 1995
ISSN: 0021-5198
DOI: 10.1016/s0021-5198(19)46622-5